T-1301 / Taivex Therapeutics Corporation, National Health Research Institutes - LARVOL DELTA

LIS22: AN EFFECTIVE MULTIMODAL POLYCLONAL ANTIBODY TARGETING T-CELL MALIGNANCIES (ICML 2025) - "LIS22 efficacy in vivo were evaluated in NMRI nude mice and SRG rats using T1301 and Jurkat cancer cell lines...In both CDC and apoptosis cytotoxicity assays, LIS22 displayed a significantly higher potency on T cell blood cancers and no toxicity on healthy blood cells compared to Alemtuzumab (Anti-CD52) and Belinostat (HDAC inhibitor)... LIS22 has emerged as a novel and promising antibody for the treatment of T-cell hematologic malignancies. It is currently under clinical investigation (Phase I/II) for the treatment of peripheral T-cell lymphoma (PTCL)."

Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Taivex Therapeutics Corporation | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Jan 2025 ➔ Jan 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

LIS22, a first in class polyclonal antibody immunotherapy in T cell blood cancers (AACR 2024) - "LIS22 efficacy in vivo were evaluated in NMRI nude mice and SRG rats using T1301 and Jurkat cancer cell lines...In both CDC and apoptosis cytotoxicity assays, LIS22 displayed a significantly higher potency on T cell blood cancers and no toxicity on healthy blood cells compared to PTCL clinically active drug Alemtuzumab (Anti-CD52)... LIS22 appeared as a novel and promising cancer immunotherapy against T Cell hematologic malignancies. It has already been administered to human in another indication and showed a satisfactory PK and safety profile (no signs of immunotoxicity or systemic cytokine release). LIS22 is now ready to enter Phase I/II in the coming months for the treatment of peripheral T cell lymphoma (PTCL)."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A phase 1 multi-center, open label, dose escalation study to evaluate the safety, pharmacokinetics (PK) and anti-tumor activity of T-1301, a novel small molecular multi-target kinase inhibitor, in patients with advanced solid tumors (AACR 2024) - P1 | "For those who benefit from the study medication after 2 treatment cycles, intra-subject dose escalation for multiple times is allowed in extension study period. Patient recruitment began in December 2021 and is ongoing in Taiwan."

Clinical • Metastases • P1 data • PK/PD data • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Sarcoma • Solid Tumor • ABL1 • FLT3

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Taivex Therapeutics Corporation

Metastases • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Pre-clinical efficacy of the first glyco-humanized oncolytic polyclonal antibody (XON7) in onco-hematology. (ASCO 2023) - "Xenograft mice model: XON7 efficacy was tested in several sub cutaneous xenograft models in NMRI nude mice (n=10 per group) using A549: non-small-cell lung cancer, HCT-116: colon cancer, LnPac: prostate cancer, KMS-12-BM: myeloma, T1301: T cell lymphoma. Immunotherapy with XON7 could be a novel therapeutic approach to fight solid tumors and hematological malignancies. >"

Preclinical • Acute Myelogenous Leukemia • Colon Cancer • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Lung Cancer • Lymphoma • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Osteosarcoma • Prostate Cancer • Sarcoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Taivex Therapeutics Corporation; Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor